Combination therapy with anti-PD-1 antibody, radiotherapy, and tyrosine kinase inhibitor for unresectable primary ectopic hepatocellular carcinoma: a case report with genomic profiling and literature review - Report - MDSpire

Combination therapy with anti-PD-1 antibody, radiotherapy, and tyrosine kinase inhibitor for unresectable primary ectopic hepatocellular carcinoma: a case report with genomic profiling and literature review

  • By

  • Peng Tang

  • Weixing Liu

  • Yating Xu

  • You Long

  • Yixiao Li

  • Jiaxin Li

  • Mingheng Liao

  • Xin Wang

  • Jin Zhou

  • Yong Zeng

  • July 14, 2026

Share

Clinical Report: Multimodal Treatment Approach for Unresectable EHCC

Background

Ectopic hepatocellular carcinoma (EHCC) is a rare malignancy that occurs outside the liver without a detectable intrahepatic primary tumor, presenting significant diagnostic and therapeutic challenges. The lack of standardized management guidelines complicates treatment decisions, particularly for unresectable cases.

Data Highlights

ParameterValue
Progression-Free Survival27 months
Overall Survival30 months

Key Findings

  • The patient was diagnosed with unresectable, multifocal EHCC localized within the abdominal cavity.
  • Comprehensive genomic analysis revealed significant upregulation of the interferon response pathway.
  • The treatment regimen included lenvatinib, camrelizumab, and stereotactic body radiotherapy.
  • The patient achieved a progression-free survival of 27 months and an overall survival of 30 months.
  • A systematic review of 55 EHCC cases provided insights into demographic and clinical characteristics.

Clinical Implications

The findings provide insights into the management of patients with unresectable EHCC.

Conclusion

This case study provides valuable genomic insights into this rare malignancy.

Related Resources & Content

  1. Frontiers in Medicine, 2026 -- Multidisciplinary treatment of follicular thyroid carcinoma with hepatic and pulmonary metastases: a case report and literature review
  2. Frontiers in Medicine, 2026 -- Case Report: Multimodal treatment for two unresectable intraductal papillary mucinous neoplasms of the bile duct and literature review
  3. BJS (British Journal of Surgery) -- Surgical Resection of Multifocal Intrahepatic Cholangiocarcinoma
  4. PubMed -- Hepatocellular carcinoma arising from ectopic liver tissue: a systematic review of the literature
  5. Comprehensive Treatment Strategies for Bilobar Colorectal Liver Metastases
  6. EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
  7. Management of Hepatocellular Carcinoma | AASLD
  8. Hepatocellular carcinoma arising from ectopic liver tissue: a systematic review of the literature - PubMed
  9. Frontiers | Challenge in Diagnosis and Treatment of Ectopic Hepatocellular Carcinoma: A Case Report and Literature Review
  10. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update | Journal of Clinical Oncology
  11. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma
  12. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma - Journal of Hepatology
  13. Three‐Year Long‐Term Outcomes in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab Treatment in Clinical Practice - PMC
  14. Three-Year Long-Term Outcomes in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab Treatment in Clinical Practice - PubMed
  15. Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma - PubMed
  16. Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC - Journal of Hepatology
  17. Baseline Liver Function and Subsequent Outcomes in the Phase 3 REFLECT Study of Patients with Unresectable Hepatocellular Carcinoma - PMC
  18. Characterization of Tumor Responses in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib in the Phase 3 Randomized Trial: REFLECT - PMC
  19. Unresectable ectopic hepatocellular carcinoma in the left sub-diaphragmatic area and retroperitoneum treated with TACE: case report and literature review - PubMed

Original Source(s)

Combination therapy with anti-PD-1 antibody, radiotherapy, and tyrosine kinase inhibitor for unresectable primary ectopic hepatocellular carcinoma: a case report with genomic profiling and literature review

  • by Peng Tang, Weixing Liu, Yating Xu, You Long, Yixiao Li, Jiaxin Li, Mingheng Liao, Xin Wang, Jin Zhou, Yong Zeng

  • July 14, 2026

Related Content

Motor mapping to enable resections of peri-rolandic diffuse gliomas

Correction: Primary malignant peripheral nerve sheath tumor of the liver: a case report and literature review

Inside VIVEbiotech’s Work with Zelluna on TCR-NK Cell Therapy

VIVEbiotech CEO Jon Alberdi lifts the lid on an eight-year collaboration focused on GMP lentiviral vectors for off-the-shelf solid tumor therapies

  • July 14, 2026

  • 4 min